Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-14T07:23:52.517Z Has data issue: false hasContentIssue false
  • English
  • Français

Opioid Substitution: More than Only Methadone!

Published online by Cambridge University Press:  01 September 2022

M. Torrens
M. Torrens*
Affiliation:
Hospital del Mar, Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Opioid misuse and its rising rates of morbidity and associated mortality is an increasing area of concern worldwide. The licit/illicit consumption of opioids ranging from plant-based substances and pharmaceutical drugs (particularly analgesia) to the new synthetic opioids, has brought opioid use disorder (OUD) back to the public health concerns, including not only prevention but also availability of evidence-based treatments. Agonist opioids have demonstrated by long high efficacy and effectiveness for OUD treatment. Although methadone has been the more prescribed drug in most of the countries where opioid agonist treatment is available, other agonist opioids can be prescribed. We will present a start of the art of other agonist opioids available for the treatment of OUD, emphasizing in the differences among them, in line with of personalizing treatment in addiction. We will focus on morphine slow release, buprenorphine (with or without naloxone, sublingual or long-lasting) and diacetylmorphine.

Disclosure

MT has been consultant/advisor and/or speaker for Gilead Sciences, Merck Sharp & Dohme Corp, Servier, Adamed, Lundbeck, Camurus, Rovi and Molteni.

Keywords

buprenorphineopioid addictionnew synthetic opioidsmethadone
Type
Pharmacology
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S42
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.